Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients (Q24246096)

6

0 references

Mical Paul

3

0 references

Karla Soares-Weiser

5

0 references

Liat Vidal

1

0 references

Ellisheva Pokroy

4

object named as

Ellisheva Pokroy

0 references

I Itsik Ben-Dor

Cochrane Database of Systematic Reviews

2

object named as

Itsik Ben dor

0 references

publication date

18 October 2004

0 references

published in

0 references

cites work

Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Oral administration of cefixime to lower risk febrile neutropenic children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Home treatment of febrile neutropenia: an empirical oral antibiotic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient antibiotherapy in children with neutropenia and fever. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Which children with fever and neutropenia can be safely treated as outpatients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Early hospital discharge of children with fever and neutropenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Multinational cooperation in trials and guidelines dealing with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Can

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Trials to assess equivalence: the importance of rigorous methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Bacterial infections in low-risk, febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Risk assessment and risk-based therapeutic strategies in febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

"Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Risk factors assessment in fabrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Predicting the risk of bacteremia in childen with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

New trends in patient management: risk-based therapy for febrile patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021

Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021

Gram-positive bacteraemia in granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021

Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003992.PUB2

7 January 2021